AXL and cancer: Concurrent inhibition of adhesion-driven plasticity (CDH2 and AXL–FAK signaling) [109], ferroptosis-resistance circuits (the GPX4–xCT antioxidant axis and the FSP1–DHODH mitochondrial pathway) [199,200,201], and exosome biogenesis or selective cargo loading (Rab27a, ALIX, YBX1) could synergistically dismantle the adaptive resilience of cancer stem-like cells [200].